Pharmacological targeting of apelin impairs glioblastoma growth by Harford-Wright, E et al.
Pharmacological targeting of apelin impairs
glioblastoma growth
Elizabeth Harford-Wright,1,2 Gwennan Andre-Gregoire,1,* Kathryn A. Jacobs,1,*
Lucas Treps,2 Sophie Le Gonidec,3 Heloise M. Leclair,1,2 Sara Gonzalez-Diest,1,2
Quentin Roux,1 Franc¸ois Guillonneau,4 Delphine Loussouarn,5,6 Lisa Oliver,5,6
Franc¸ois M. Vallette,6,7 Fabienne Foufelle,8 Philippe Valet,3 Anthony P. Davenport,9
Robert C. Glen,10,11 Nicolas Bidere1,2 and Julie Gavard1,2
*These authors contributed equally to this work.
Glioblastoma are highly aggressive brain tumours that are associated with an extremely poor prognosis. Within these tumours
exists a subpopulation of highly plastic self-renewing cancer cells that retain the ability to expand ex vivo as tumourspheres, induce
tumour growth in mice, and have been implicated in radio- and chemo-resistance. Although their identity and fate are regulated by
external cues emanating from endothelial cells, the nature of such signals remains unknown. Here, we used a mass spectrometry
proteomic approach to characterize the factors released by brain endothelial cells. We report the identiﬁcation of the vasoactive
peptide apelin as a central regulator for endothelial-mediated maintenance of glioblastoma patient-derived cells with stem-like
properties. Genetic and pharmacological targeting of apelin cognate receptor abrogates apelin- and endothelial-mediated expansion
of glioblastoma patient-derived cells with stem-like properties in vitro and suppresses tumour growth in vivo. Functionally,
selective competitive antagonists of apelin receptor were shown to be safe and effective in reducing tumour expansion and
lengthening the survival of intracranially xenografted mice. Therefore, the apelin/apelin receptor signalling nexus may operate
as a paracrine signal that sustains tumour cell expansion and progression, suggesting that apelin is a druggable factor in
glioblastoma.
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Abbreviations: EC-CM = endothelial cell conditioned media; GSC = glioblastoma stem-like cells; MF = mitogen-free;
NS = mitogen-supplemented; TMZ = temozolomide
Introduction
Glioblastoma is the most common and lethal primary brain
tumour in adults. Although there has been notable progress
in strategies to ﬁght glioblastoma (Stupp et al., 2009;
Chinot et al., 2014; Brown et al., 2016), the prognosis
remains extremely poor with average survival reported to
be less than 15 months following diagnosis (Stupp et al.,
2009, 2015). A subpopulation of tumorigenic cells termed
glioblastoma stem-like cells (GSCs), also known as cancer-
initiating cells (Lathia et al., 2015), has been implicated in
tumour initiation, resistance to current therapies and dis-
ease recurrence (Singh et al., 2004; Bao et al., 2006; Chen
et al., 2012; Yan et al., 2013). Similar to how normal stem
and progenitor cells participate in tissue development and
repair, cancer stem-like cells pervert these processes to fa-
cilitate the initiation and progression of tumours.
Moreover, GSCs contribute to both radiation and chemo-
resistance as these treatments target cycling, highly prolif-
erative cancer cells, whereas GSCs are comparatively
quiescent, and thus survive to repopulate the tumour
post-treatment (Bao et al., 2006; Chen et al., 2012). As
such, GSCs represent an important target for future thera-
pies and a better understanding of how GSCs interact with
their environment is required.
Studies have proposed that GSC tumorigenicity relies on
the surrounding tumour microenvironment, with brain
tumour-initiating cells reported to reside in close contact
with brain microvascular cells (Calabrese et al., 2007;
Galan-Moya et al., 2011; Shingu et al., 2017). The local-
ization of GSCs in proximity to endothelial cells facilitates
communication between these cells (Calabrese et al., 2007)
allowing the tumour vascular bed to provide factors essen-
tial to maintain GSC resistance to therapies, identity and
fate (Garcia-Barros et al., 2003; Folkins et al., 2007; Evers
et al., 2010; Galan-Moya et al., 2011, 2014). Among the
putative candidates of this angiocrine signalling, soluble
growth factors emanating from the vascular niche have
been reported in various physiological and pathological
models (Andreu-Agullo et al., 2009; Beck et al., 2011;
Cao et al., 2014, 2017). However, to date, the speciﬁc
endothelial secreted factors involved in this process
remain to be identiﬁed. Here, we used a mass spectrometry
proteomic analysis of the endothelial cell secretome and
identiﬁed the vasoactive peptide apelin as a central regula-
tor of the expansion of glioblastoma patient-derived cells
with stem-like properties. As such, targeting apelin may
represent an effective novel therapeutic approach to treat
glioblastoma.
Materials and methods
Ethics statement
Informed consent was obtained from all patients prior to
sample collection for diagnostic purposes. Clinical tissue sam-
ples were provided by the Regional Institute for Cancer in
Nantes Atlantique (IRCNA) tumour library (Nantes, France).
This study was reviewed and approved by the institutional
review boards of Sainte Anne Hospital, Paris, France, and
Laennec Hospital, Nantes, France, and performed in accord-
ance with the Declaration of Helsinki Protocol. Animal pro-
cedures were conducted as outlined by the European
Convention for the Protection of Vertebrate Animals used
for Experimental and other Scientiﬁc Purposes (ETS 123)
and approved by the French Government (APAFIS#2016-
2015092917067009).
Analysis of human clinical databases
The Cancer Genome Atlas (TCGA, HG-UG133A and Agilent-
4502A data), Rembrandt and Gravendeel microarrays were
interrogated through the Gliovis platform (http://gliovis.
bioinfo.cnio.es/) (Bowman et al., 2017). Data were plotted
based on histology criteria only. For reverse protein phase
arrays (RPPA), optimal cut-offs were set to deﬁne high
versus low expression of APLNR, as indicated on the plots.
Pairwise t-tests were run.
Cell culture, conditioned media pre-
paration and mass spectrometry
Glioblastoma patient-derived cells with stem-like properties
(GSCs) were isolated as previously described (Treps et al.,
2016). Brieﬂy, tumours were dissociated using the
MACsDissociator (Miltenyi) and each GSC characterized for
their self-renewal capabilities, cell surface antigens, expression
of stemness markers, their ability to differentiate, and to initi-
ate tumour formation (Supplementary Table 1). GSCs 1–16
were maintained as spheres in NS medium (DMEM-F12,
with N2, G5 and B27 supplements, GlutaMAXTM and antibi-
otics, Life Technologies). To induce differentiation in GSCs,
the three supplements were omitted and 10% foetal bovine
serum added to the media.
Human brain microvascular endothelial cells (hCMEC/D3,
PO Couraud), HEK-293T and SVEC4-10 mouse endothelial
cells (ATCC) were cultured as previously described (Treps
et al., 2016). Tumour-derived endothelial cells (tEC) were iso-
lated from mechanically homogenized mice orthotopic brain
tumours using CD31 MicroBeads (Miltenyi).
Stealth non-silencing control (low-GC 12935111) and se-
lected siRNA targeting human APLN (HSS113086), APLNR
(HSS100325) and GSK3B (HSS104522) (Life Technologies,
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50 nM) were transfected using RNAiMAX Lipofectamine
(Life Technologies). GIPZ lentiviral shRNAs against human
APLNR sequences 1–3, with identiﬁcation numbers
V3LHS_307344, V3LHS_307345 and V3LHS_307346, re-
spectively, were purchased from Thermo Fisher Scientiﬁc.
Lentiviral particles were collected from pGIPZ, pSPAX2 and
pVSVg co-transfected HEK-293T cells (Dubois et al., 2014).
Conditioned media (CM) from hCMEC/D3 (hEC-CM),
tumour xenograft-derived endothelial cells (tEC-CM),
SVEC4-10 (mEC) and HEK-293T (293T-CM) cells were ob-
tained from 72-h-old monolayers in serum-free EBM2 (Lonza).
Conditioned media from GSC#1 was obtained from 72-h-old
tumourspheres. For acidic stress simulation, EBM2 (Lonza, pH
8.2) was adjusted to pH 6.8 using HCl before preparing hEC-
CM. Apelin concentrations were quantiﬁed using the human
apelin-12 EIA kit according to the manufacturer’s instructions
(cross-reactivity with apelin-12, apelin-13, and apelin-36,
Phoenix Pharmaceuticals).
Protein and peptide identiﬁcation was performed in the
University Paris Descartes Proteomics Facility (3P5, Paris,
France), without trypsin proteolysis for peptidome analysis,
as previously described in Luissint et al. (2012). Mass spectra
were measured with a 4800 MALDI-TOF-TOF mass spec-
trometer (ABSciex) equipped with a Nd:YAG pulsed laser
(355 nm wavelength, 5500 ps pulse and 200Hz repetition
rate). Spectra acquisition and processing were performed
using the 4000 series explorer software (ABSciex).
Drugs
MM54 (cyclo[1-6]CRPRLCKHcyclo[9-14]CRPRLC) and
MM193 were prepared as previously described (Macaluso
et al., 2011). Temozolomide (TMZ) and tideglusib were pur-
chased from Sigma, and apelin peptides were from Phoenix
Pharmaceuticals (pyr1-apelin-13 pyr1-QRPRLSHKGPMPF,
apelin-13 QRPRLSHKGPMPF, and apelin-36 LVQPRGSRN
GPGPWQGGRRKFRRQRPRLSHKGPMPF).
Tumoursphere formation
To test the tumoursphere formation, GSCs (100 cells/ml) were
plated in triplicate in indicated media as previously described
(Harford-Wright et al., 2016). Cells were manually dissociated
each day and a single cell suspension maintained until Day 5.
Tumourspheres were counted in ﬁve random ﬁelds of view,
and the mean from the triplicate of each condition calculated
from three independent experiments.
Limiting dilution assays
To test the clonal capacity of GSCs, a limiting dilution assay
was performed as previously described (Tropepe et al., 1999).
GSCs were seeded in the tested media (NS, MF and EC-CM)
in a 96-well plate with serial dilutions ranging from 4 to 2000
cells/well, with eight wells per dilution for each plate and trea-
ted as indicated. Two weeks later, each well was scored for
tumoursphere formation and the frequency of stem cells calcu-
lated using ELDA software (Hu and Smyth, 2009). The mean
stem cell frequency for each condition was determined by aver-
aging the stem cell frequencies of two independent
experiments.
Radioligand binding and calcium
mobilization assays
Radioligand binding and calcium mobilization assays to assess
the putative off-target effects of MM54 were performed by
Euroﬁns Cerep Panlabs, according to the manufacturer’s
instructions.
Cell viability
Cell viability in response to MM54 was tested using the
UptiBlue reagent (Interchim), a ﬂuorometric/colorimetric
growth indicator based on the detection of metabolic activity.
Brieﬂy, cells were seeded at a density of 2  103 per well,
UptiBlue added at a concentration of 10% v/v and cells main-
tained at 37C 5% CO2 until analysis. Absorbance was mea-
sured at Day 5 following treatment at 570 and 600nm on a
FLUOStar OPTIMA (BMG Labtech) plate reader, and the per-
centage of cell viability calculated according to the manufac-
turer’s instructions.
Cell survival in adherent cells was evaluated using the MTT
assay [1-(4,5-dimethylthiazol-2-yl)-3,5-diphenylformazan, thia-
zolyl blue formazan; Sigma], which is reduced to formazan
based on the mitochondrial activity of living cells. Cells were
seeded in a 96-well plate in triplicate at a density of 5  103
per well and treatments administered 24 h after seeding.
Absorbance values were read at 590 nm and expressed as a
percentage of cell viability relative to basal conditions.
Animal procedures
Tumour inoculation experiments were performed on female
Balb/C nude mice (Janvier) aged 5–6 weeks. For toxicity ex-
periments 6-week-old female C57/Bl6J (Janvier) mice were
used. Animals were randomly assigned to each group and
group housed in speciﬁc pathogen-free conditions at 24C on
a 12-h day-night cycle. At all times, animals were allowed
access to standard rodent pellets and water ad libitum.
To test potential toxic effects of MM54 and MM193
in vivo, mice were administered 2mg/kg of MM54, MM193
or vehicle bi-weekly for 4 weeks. At sacriﬁce, blood was taken
for analysis and the heart, kidney, aorta and liver removed,
weighed and ﬁxed for histological analysis. For the glycaemic
study, animals were starved for 6 h prior to sacriﬁce.
For the ectopic models, mice were subcutaneously injected
with 5  105 GSC#9 in 100ml of phosphate-buffered saline
(PBS) and growth factor-free Matrigel (Corning) in each
ﬂank. Tumourspheres were dissociated prior to injection for
all in vivo experiments to ensure implantation of a single cell
suspension. To analyse tumour initiation, mice were examined
weekly to monitor tumour growth and sacriﬁced between 6
and 7 weeks following implantation. For pharmacological stu-
dies, mice were treated twice per week once tumours were
palpable, with MM54 (2mg/kg), MM193 (2mg/kg) or vehicle
(PBS) by intraperitoneal injection. Tumour size was measured
once a week with callipers and tumour volume calculated
using the following equation (width2  length)/2.
Intracranial injection of GSC#9 was performed using a free
hand injection technique as described in detail elsewhere (Treps
et al., 2016). Brieﬂy, mice were anaesthetized with a mixture of
ketamine (100mg/kg) and xylazine (10mg/kg) and a midline
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incision performed. A small burr hole was made 2mm to the
right of bregma, 1mm anterior and 3mm ventral to the coronal
suture. A 5ml Hamilton syringe was inserted to a depth of 3mm
and 105 GSC#9 injected slowly. One minute after completion of
the injection, the needle was retracted, surgical site closed and
animals allowed to recover. At 3 weeks following GSC#9 in-
oculation, treatment with PBS or MM54 (2mg/kg) was com-
menced three times per week until death due to tumour burden
or the conclusion of the experiment at Day 70.
Immunostaining
Both cellular and tissue analysis was performed using immunos-
taining and haematoxylin and eosin standard protocols (Treps
et al., 2016). The following primary antibodies were used:
PECAM (BD), pS9-GSK3b (Cell Signaling), APLN and
APLNR (Abcam), and Ki67, SOX2 and NESTIN (Millipore).
Cell death was estimated through the TUNEL assay kit
(Trevigen). A minimum of three tumour sections per condition
was used for analysis, with at least ﬁve different ﬁelds of view.
For blood vessel surface analysis, PECAM pixel intensity was
calculated (ImageJ) in randomly chosen ﬁelds of view and
mean  standard error of the mean (SEM) of the total ﬁeld of
view was represented. Cell proliferation was assessed through
the percentage of Ki67-positive cells normalized to the total
number of nuclei. NESTIN-positive and pS9-GSK3b-positive
cells were counted per ﬁeld of view. Image acquisitions were
performed on Spinning Disk Leica microscope (Institut
Cochin) and confocal Nikon A1 RSi (Micropicell).
Flow cytometry
For cell surface expression analysis, cells were incubated with
antibodies for 1 h and washed twice with cold PBS. For total
expression, cells were ﬁxed (4% paraformaldehyde-PBS,
15min) and permeabilized (iced-cold methanol, 10min) prior
incubation with antibodies. APC-APLNR, and isotype control
Ig (R&D systems) antibodies were used.
Analysis of aldehyde dehydrogenase (ALDH) activity was per-
formed using the ALDEFLUORTM assay kit (Stem Cell
Technologies). Brieﬂy, cells were incubated with ALDEFLUOR
alone or in combination with an ALDH activity inhibitor
(DAEB) at 37C for 45min. This ﬂow cytometry-based staining
allows monitoring ALDH activity in stem, progenitor and
cancer precursor cells. The ALDH activity is considered positive
in comparison to cells incubated with DEAB reagent.
Flow cytometry analyses were performed on Accuri C6 and
FACsCalibur (BD Biosciences, Cytocell) and processed using
CFlow plus or FlowJo software (BD Biosciences).
Western blots
Following stimulation with the relevant treatment, cells were
collected and washed in PBS before lysis at 4C with TNT
buffer (50mM Tris pH 7.4, 150mM NaCl, 2mM EDTA,
1% TritonTM X-100, 1% IGEPAL) supplemented with prote-
ase inhibitors (ThermoFisher Scientiﬁc). Equal amounts of pro-
tein were loaded on tris-glycine gels and transferred onto
nitrocellulose membranes (GE Healthcare). Antibodies against
pS9-GSK3b, GSK3b, KDM1A, pS473-AKT, AKT, pS235/
S236-S6 and pT202/Y204-ERK1/2 (Cell Signaling, Ozyme),
GAPDH (Santa Cruz Biotech) and APLNR (Abcam) were
incubated with the membrane overnight at 4C and followed
by incubation with the relevant secondary antibodies (Southern
Biotech) for 1 h at room temperature. Membranes were revealed
using a chemiluminescent HRP substrate (Millipore) and visua-
lized using the Fusion imaging system (Vilber Lourmat).
RNA extraction and RT-PCR
RNA was extracted using the Qiagen RNeasy Mini Kit as per
the manufacturer’s directions. Equal amounts of RNA were
reverse transcribed using the SuperScript III RT kit (Life
Technologies) and the resulting cDNA was used to amplify
mRNA by PCR using gene-speciﬁc primer sets in the presence
of REDTaq DNA polymerase (Sigma). ACTB and GAPDH
were also ampliﬁed as control for input. See Supplementary
Table 2 for primer details.
Statistics
Data are representative of three independent experiments,
unless otherwise stated. Statistical analysis was performed
with GraphPad Prism6 using two-way ANOVA and an un-
paired two-tailed t-test (Student’s t-test). In Kaplan-Meier sur-
vival curves, differences were compared by log-rank analysis
and Gehan-Breslow-Wilcoxon. In all experiments a P-value of
50.05 was considered signiﬁcant.
Results
Endothelial cells produce the
vasoactive peptide apelin
To identify endothelial-secreted factors potentially involved in
the maintenance of GSCs, we performed an unbiased tandem
mass spectrometry proteomic analysis of the human brain
endothelial secretome using human brain endothelial cell
(hCMEC/D3)-conditioned media (EC-CM) and compared it
to epithelial-like HEK-293T CM. Hits that were shared by
the two cell lines were discarded, and 22 peptides or proteins
speciﬁc to the EC-CM identiﬁed (Fig. 1A, Supplementary
Table 3 and Supplementary Fig. 1A). Apelin peptides re-
vealed the highest exponentially modiﬁed protein index and
were selected for further characterization (Fig. 1B,
Supplementary Table 3 and Supplementary Fig. 1B and C).
Enzyme immunoassay analysis demonstrated that endo-
thelial cells secreted signiﬁcant amounts of apelin, as the
peptide was robustly detected in the conditioned media
produced by human, mouse and xenograft tumour-derived
endothelial cells, supporting endothelial cells as a source of
apelin (Fig. 1C and D). In contrast, apelin was not detected
in patient-derived GSC#1, #2, #9 and #12 RNA lysates,
and concentrations were found lower than the limit of
ELISA sensitivity (0.07 ng/ml) (Fig. 1C and D).
Furthermore, to challenge apelin production in conditions
that recapitulate the tumour microenvironment, we as-
sessed apelin secretion from human brain endothelial cells
under acidic stress (Fig. 1D). Interestingly, acidiﬁcation of
the milieu did not affect the overall production of apelin.
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Figure 1 Endothelial cells produce the vasoactive peptide apelin. (A) Mass spectrometry analysis of the brain microvascular endothelial
cell (hEC) secretome identified 22 peptides and proteins specific to endothelial cells. (B) Apelin peptide coverage (37%) is indicated in red on the
full-length sequence. (C) RT-PCR for APLN and GAPDH is shown for hEC and glioblastoma patient-derived cells with stem properties (GSCs) #1,
#4, #9 and #12 RNA total cell lysates. (D) Apelin secretion in mitogen-free control media (MF), and in conditioned media (CM) prepared from
GSC#1, human brain microvascular EC (hEC), mouse macrovascular EC (mEC) and orthotopic mouse brain tumour-isolated EC (tEC). Apelin
secretion was measured in CM from hEC cultured in acidified medium (pH 6.8) or control conditions (pH 8.2). Data are representative of n5 2
with mean  SEM. Red dashed lines indicate the minimum sensitivity range of APLN detection. (E) Confocal analysis of SOX2 (green) + PECAM
(red), APLN (green) + PECAM (red), APLN (green) + NESTIN (red), NESTIN (green) + APLNR (red) in glioblastoma clinical samples. Nuclei are
shown in blue (DAPI). Arrowheads and arrows indicate APLNR/NESTIN and APLN/PECAM-double positive cells respectively. Scale bars = 25 mm.
Data are representative of n = 4 newly diagnosed patient samples. All panels are representative of n = 3, unless specified.
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Moreover, we detected apelin and its receptor, the
G-protein coupled receptor APLNR (APJ), in clinical glio-
blastoma samples in the vicinity of PECAM-labelled endothe-
lial cells and cells positive for the stem cell markers NESTIN
and SOX2 (Fig. 1E), suggesting a potential role for apelin in
the tumour vascular niche (Calabrese et al., 2007). However,
APLN staining did not coincide with NESTIN-positive
tumour cells, but rather with vascular tracks (Fig. 1E), sup-
porting endothelial cells as a potential source for apelin in
glioblastoma, consistent with a recent report in colorectal
cancer-derived endothelial cells (Zuurbier et al., 2017). To
explore the clinical relevance of apelin further, we performed
a retrospective analysis using The Cancer Genome Atlas
(TCGA), Rembrandt and Gravendeel databases. Analysis of
all three databases revealed a signiﬁcant increase in APLN
mRNA in glioblastoma tissue, as compared to non-tumour
samples, which might be due to endothelial abundance in
these grade IV tumours (Supplementary Fig. 1D).
Apelin sustains GSC expansion
in vitro
We next evaluated the response of patient-derived GSCs,
which have been extensively characterized both in vitro and
in vivo (Supplementary Table 1 and Supplementary Fig. 2A
and B) to the biologically active apelin fragments: apelin-
13, pyr-apelin-13 and apelin-36 (see ‘Materials and meth-
ods’ section for more information). Although all of the
apelin peptides increased the number of tumourspheres
compared to mitogen-free media (MF), apelin-13 was the
most potent at sustaining GSCs (Fig. 2A). Subsequently, we
assessed the effect of increasing concentrations of apelin-13
(termed apelin hereafter) on GSC#1 and observed a potent
and sustained increase in tumourspheres from the lowest
concentration (Fig. 2B). Consistent with our previous
work (Galan-Moya et al., 2011, 2014), both mitogen-sup-
plemented medium (NS) and EC-CM maintained the ex-
pression of stem markers NESTIN and SOX2 (Fig. 2C).
Accordingly, mitogen withdrawal resulted in the loss of
expression of these markers and the reduced ability to
form tumourspheres, which was rescued by the addition
of synthetic apelin to this MF media (Fig. 2C). To deter-
mine whether apelin alone maintained GSC self-renewal, a
limiting dilution assay was performed in GSC#1 (Fig. 2D).
As expected, we observed the highest frequency of colony-
forming cells in GSCs grown in NS and EC-CM.
Nonetheless, compared to MF conditions, GSC#1 grown
in apelin-supplemented MF demonstrated an increase in
the frequency of colony-forming cells. Moreover, we
observed in a panel of 16 patient-derived GSCs
(Supplementary Table 1) that apelin-supplemented media
signiﬁcantly increased the ability of GSCs to expand as
tumourspheres (Fig. 2E), and increased the frequency of
stem cells in a panel of ﬁve representative GSCs (Fig. 2F),
indicating that in vitro apelin addition sustains GSC growth
and substitutes, at least partially, to cell culture
supplements provided in the NS (Fig. 2D–F). Similar effects
were obtained with apelin-containing conditioned media
derived from mouse brain tumour endothelial cells (tEC-
CM) (Figs 1C and 2G), indicating that tumour-derived
endothelial cells may provide a source of bioactive apelin
in situ, although the intratumoural concentration and the
apelin forms are not experimentally available. Consistent
with these ﬁndings, EC-CM obtained from APLN-silenced
endothelial cells was no longer able to maintain the stem
properties of GSCs, while the addition of exogenous apelin
into the depleted EC-CM restored this effect (Fig. 2H–J).
Furthermore, we did not observe any obvious effect of
apelin-supplemented mitogen-free media on the prolifer-
ation of GSCs (Fig. 2K), indicating that apelin may main-
tain GSCs by enhancing their self-renewal capabilities.
Apelin modulates GSCs via activation
of the G-protein coupled receptor
APLNR
Apelin is known to signal through the G-protein coupled
receptor APLNR (also known as APJ), which is reported
to be highly expressed throughout the brain and act as para-
crine and autocrine factor that supports embryonic and
tumour angiogenesis (Kaelin et al., 2007). In the present
study, we observed a heterogeneous expression of APLNR
in our panel of GSCs, at both a RNA and protein level (Fig.
3A and B). In keeping with a role for apelin in the stem cell
maintenance, we found that differentiated GSCs were asso-
ciated with a decrease in APLNR expression compared to
tumourspheres (Fig. 3C and D) and reduced tumour-initiat-
ing ability (Supplementary Fig. 2C). Moreover, analysis of
the stem marker PROM1 (CD133) revealed that expression
of APLNR was detected in the PROM1 (CD133)-positive
GSC population, further supporting a role for apelin and
its receptor in the stem population (Fig. 3E). Consistent
with this, APLNR silencing in GSC#1 impaired the ability
of these cells to form SOX2-positive spheres cultured in both
EC-CM and apelin conditions (Fig. 3F and G). Of note, the
optimal concentration of exogenous mitogens in the NS
medium allows maintaining APLNR-knocked down
GSC#1 expansion in vitro (Fig. 3F and G). Similar results
were obtained in three additional GSCs with variable
APLNR expression level (Fig. 3A, B and H), highlighting
the potential importance of this receptor in GSC mainten-
ance in response to APLN. Subsequently, GSC#9 was trans-
duced with short hairpin (sh) RNA against APLNR and
grafted subcutaneously into the ﬂanks of nude mice.
Reducing APLNR levels in GSC#9 markedly decreased
tumour development, NESTIN overall staining and only
mildly affect tumour vascularization (Fig. 3I and J). To ob-
serve the impact of APLNR signalling on tumour develop-
ment in the brain microenvironment, shAPLNR GSC#9 were
orthotopically implanted into the striatum of nude mice and
assessed for histological signs of tumour growth at Week 5,
when tumours are largely developed but neurological signs
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were not yet evident. In these conditions, the number of
progressing tumours was modestly reduced in APLNR
shRNA (Supplementary Fig. 2D). Whether the reduction of
APLNR expression also decreases tumour volume would
require in-depth measurement over time. This slight decrease
in tumour formation suggested that APLNR contributes to
tumour expansion, although compensatory mechanisms may
take place due to alternate signalling or an incomplete
knockout of APLNR gene. Collectively, these results suggest
that endothelial-secreted apelin sustains GSCs both in vitro
and in vivo via activation of the apelin receptor.
Pharmacological inhibition of APLNR
impairs the effects of the endothelial
secretome on GSCs by inhibition of
GSK3b signalling
To next evaluate the potential of targeting apelin/APLNR,
we investigated the properties of a novel bi-cyclic peptide
[cyclo(1–6)CRPRLC-KH-cyclo(9–14)CRPRLC], MM54,
which acts as a competitive antagonist of APLNR (Fig.
4A) (Macaluso et al., 2011; Brame et al., 2015). To identify
Figure 2 Apelin sustains GSC expansion in vitro. (A) Tumoursphere per field of view (fov) in GSCs #1, #9, #12 and #13 in response to
apelin 13 (APLN-13), pyr-apelin-13 (pyr-APLN-13) or apelin 36 (APLN-36) treatment (1mM, diluted in mitogen-free medium, MF). **P5 0.01,
*P5 0.05 compared to the MF condition. (B) Tumourspheres per field of view were counted in GSC#1 cultured in complete mitogen-supple-
mented medium (NS), MF and MF supplemented with the indicated APLN concentration. ***P5 0.001 compared to the MF condition.
(C) Confocal analysis of NESTIN (green), SOX2 (red) and nuclei (DAPI, blue) in GSC#1 grown in NS, MF, human brain endothelial cell-conditioned
medium (EC-CM) or MF + APLN (1mM). Scale bars = 20mm. (D) Linear regression plot of in vitro limiting dilution assay (LDA) for GSC#1 in NS, EC-
CM, MF, and MF + APLN (1mM). Data are representative of n = 2. (E) Tumourspheres per field of view were quantified in GSCs #1 to #16 cultured
in MF or with apelin. *P5 0.05; **P5 0.01; ***P5 0.001 compared to the MF condition. (F) Stem cell frequency in GSCs #1, #2, #4, #9 and #12 in
response to MF and APLN conditions. (G) Tumourspheres per field of view in GSC #1 in NS, MF and EC-CM derived from mouse tumour
endothelial cells (tEC-EM). **P5 0.01 compared to the MF condition. (H) EC received non-silencing RNA (sic) or siRNA targeting APLN (siAPLN)
and APLN knockdown efficiency assessed by RT-PCR and ELISA. (I and J) GSCs #1 were cultured with sic and siAPLN EC-CM, with or without
apelin (1mM). **P5 0.01 compared to the corresponding control condition for both tumoursphere and LDA assays. (K) FACS analysis of the
proliferation marker Ki67 in GSCs #4 and #9 in NS and MF + APLN conditions. All panels are representative of n = 3, unless otherwise specified.
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possible off-target G-protein coupled receptor or ion chan-
nels that may interact with MM54, we performed radioli-
gand competitive binding experiments to investigate the
speciﬁcity of the compound. MM54 inhibited more than
95% of apelin binding to APLNR at the dose of 10 mM
(Fig. 4B). In addition to APLNR, of the 55 receptors tested,
ﬁve G-protein coupled receptors (CXCR2, M3, NK2, NOP,
and 5HT1B) and one ion channel (SKCa) demonstrated
over 50% inhibition of agonist binding in response to
MM54 (10 mM) (Fig. 4B). However, using a cell-based
second messenger assay to measure G-protein coupled re-
ceptor-mediated calcium ﬂux we again observed that
MM54 was very effective at inhibiting APLNR, while
having little or no effect towards other identiﬁed off-targets
(Fig. 4C). Thus, MM54 may behave as a potent and select-
ive inhibitor of apelin binding and APLNR activation. In
both EC-CM and apelin-supplemented mitogen-free (MF)
media, MM54 induced a dose-dependent decrease in the
number of tumourspheres that was signiﬁcant from a con-
centration of 2 mM (Fig. 4D). In keeping with this, we
observed a signiﬁcant reduction in the frequency of
sphere-forming cells in GSCs #1, #4, #9 and #12 following
treatment with MM54 (Fig. 4E and F). Furthermore, inhib-
ition of APLNR with MM54 clearly decreased the percent-
age of the stem marker aldehyde dehydrogenase (ALDH)-
positive cells compared to untreated GSC#1 controls (Fig.
4G), consistent with the MM54-mediated decrease in the
number of SOX2- and NESTIN-positive spheres (Fig. 4H).
However, GSC#1 were resistant to MM54 treatment when
cultured in mitogen-containing deﬁned medium (NS) that
does not contain apelin, consistent with our RNA interfer-
ence data (Fig. 3). Analysis of downstream mechanisms
Figure 3 Apelin modulates GSCs via activation of the G-protein coupled receptor APLNR. (A) RT-PCR in a panel of 16 GSCs for
APLNR and stemness markers NES and SOX2. ACTB is shown as internal PCR control. (B) FACS analysis of APLNR surface expression in GSCs #1,
#4, #9, #12 and #13. (C and D) Differentiation was induced in GSCs #1 and #9 by growth in serum-containing media. RT-PCR and FACS analysis
of APLNR and stem markers in GSCs #1 and #9 grown as both tumourspheres (sph.) and differentiated adherent cells (adh.). (E) FACS analysis of
the stemness marker PROM1 (CD133) and APLNR in GSCs #4 and #9. Data are representative of n = 2. (F) GSC #1 received non-silencing RNA
(sic) or APLNR targeting siRNA (siAPLNR) and were maintained in complete medium (NS), human brain endothelial cell-conditioned medium (EC-
CM), and MF supplemented with purified apelin (APLN, 1 mM). Confocal analysis of SOX2 (red) and nuclei (DAPI, blue). Scale bars = 20mm.
(G) Tumourspheres per field of view (fov) in sic (small interfering control) or siAPLNR GSC#1 maintained in NS, EC-CM or APLN. APLNR
knockdown was assessed with RT-PCR. **P5 0.01; ***P5 0.001 compared to the sic condition. (H) Tumourspheres per field of view in non-
silencing duplexes (sic) or APLNR targeting siRNA (siAPLNR) transfected GSC#4, #9 and #12 in MF alone or supplemented with APLN. (I) GSCs#9
were infected with control shRNA (shc, black), and shRNA targeting APLNR (seq#1, orange; seq#2, yellow; and seq#3, red). Knockdown efficiency
was checked by western blots. Female nude mice were implanted with 5  105 shcontrol (black line), shAPLNR seq#1 (orange line) or seq#3 (red
line) and monitored for tumour-free survival over 7 weeks. n = 4 mice/group. (J) Sections of tumour tissue were analysed for PECAM and
NESTIN expression using immunofluorescence. Scale bar = 40 mm. N5 4 mice/group. All panels are representative of n = 3, unless specified.
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Figure 4 Pharmacological inhibition of APLNR impairs the effects of the endothelial secretome on GSCs by inhibition of
GSK3b signalling. (A) Molecular structure and primary sequence of the competitive APLNR antagonist MM54. (B) A radioligand binding assay
of 55 G-protein coupled receptors and ion channels identified APLNR (indicated in red) and six putative off-targets (indicated in blue) that
demonstrated 450% inhibition of agonist binding following administration of APLNR antagonist MM54 (10 mM). (C) The percentage of calcium
flux inhibition following MM54 treatment (0.4–10 mM) in the G-protein coupled receptor hits. (D) Tumoursphere per field of view (fov) in
response to MM54 (0–4 mM) treatment in GSC#1 maintained in human brain endothelial cell-conditioned medium (EC-CM) and apelin-supple-
mented mitogen-free MF media (APLN, 1 mM) for 5 days. *P5 0.05 compared to EC-CM DMSO control, #P5 0.05 compared to apelin DMSO
control. (E) Linear regression plot of in vitro limiting dilution assay (LDA) for GSC#1 in EC-CM or EC-CM + MM54 (2 mM). (F) Stem cell
frequency in apelin supplemented media in response to MM54 (2 mM) in GSCs #1, #4, #9 and #12. *P5 0.05 compared to the vehicle condition.
Apelin signalling in glioma growth BRAIN 2017: Page 9 of 16 | 9
(continued)
Downloaded from https://academic.oup.com/brain/article-abstract/doi/10.1093/brain/awx253/4316093/Pharmacological-targeting-of-apelin-impairs
by University of Cambridge user
on 06 October 2017
associated with apelin/APLNR activation revealed that
MM54 did not induce any changes to major components
of the PI3K/AKT and ERK signalling pathways (Fig. 4I).
To explore the APLNR downstream signalling further, we
interrogated the TCGA database for reverse phase protein
array (RPPA) in glioblastoma patients with high and low
APLNR expression (Fig. 4J). This analysis unmasks two
signiﬁcantly upregulated phospho-proteins, namely pYAP
and pMET, and three downregulated (pRb, pPDK1, and
pGSK3b) in high APLNR glioblastoma samples (Fig. 4J).
Interestingly, glycogen synthase kinase 3b (GSK3b) activity
has recently been shown to participate in gliomagenesis via
maintenance of the stem population of cancer cells (Zhou
et al., 2016). This process occurs through the GSK3b-de-
pendent stabilization of KDM1A. Moreover, GSK3b inacti-
vation by phosphorylation on serine 9 was associated with
a loss of stemness traits in GSCs (Zhou et al., 2016). In
keeping with this, incubation with MM54 (2mM, over-
night) in apelin-supplemented MF media resulted in an in-
crease in phosphorylation of GSK3b at serine 9 in both
GSCs #1 and #9 (Fig. 4K), consistent with an inhibitory
effect on GSK3b signalling. Consequently, we treated pa-
tient-derived GSCs with the GSK3b inhibitor tideglusib
(2.5 mM) and observed that apelin was less potent at
increasing tumourspheres and self-renewal (Fig. 4L and
M). Furthermore, silencing GSK3b in GSC#1 resulted in
a signiﬁcant decrease in apelin-mediated tumoursphere for-
mation (Fig. 4N), suggesting that apelin may sustain GSCs
via activation of GSK3b signalling.
Pharmacological inhibition of APLNR
by MM54 impairs the in vitro expan-
sion of temozolomide-resistant GSCs
The chemotherapeutic agent TMZ is commonly used in the
treatment of glioblastoma, although it has been reported
that GSCs are resistant to TMZ (Chen et al., 2012; Hale
et al., 2013). To test the speciﬁcity of MM54 towards
GSCs, we treated a panel of normal human and primary
glioblastoma cell lines with increasing concentrations of
MM54, as compared to TMZ. MM54 demonstrated no
overtly toxic effects on any of the cell lines tested, whilst
TMZ signiﬁcantly reduced the viability of glioblastoma cell
lines (namely U87 and LN229) but not GSCs (Fig. 5A and
B). Similarly to GSC#1, #4, #9 and #12, the in vitro via-
bility of U87 glioblastoma cell line grown as spheroids was
not modiﬁed upon high dose of TMZ (Fig. 5C).
Conversely, TMZ reduces the viability of U87 glioblastoma
cell line and GSCs #1, #4 and #9, when grown as adherent
differentiated cells (Fig. 5C).
Combined treatment of MM54 with TMZ did not sig-
niﬁcantly alter GSC#1 viability in NS or EC-CM even at
the highest concentrations of both compounds (Fig. 5D).
Moreover, MM54 was signiﬁcantly better at impairing
GSC#1 tumoursphere formation and ALDH activity at
low doses compared to TMZ, which required much
higher concentrations to achieve comparable results
(Fig. 5E and F). Drugs were then combined at constant
MM54:TMZ ratios (1:2.5, 1:5, and 1:10) and ALDH ac-
tivity measured (Fig. 5E). At MM54 suboptimal dose, i.e.
52 mM MM54 (Fig. 4), TMZ signiﬁcantly potentiates the
effects of MM54. To further assess whether MM54 and
TMZ do synergize, data were processed according to the
Chou combination index (CI) method (Chou, 2010)
(Fig. 5G). In this representation, a CI value of 1 indicates
an additive effect, 51 synergism and 41 antagonism.
TMZ and MM54 therefore displayed a striking synergism
(Fig. 5H). In line with this, co-administration of low doses
of both MM54 (0.5 mM) and TMZ (1.25, 2.5, and 5 mM)
decreased the percentage of ALDH activity in GSCs
(Fig. 5I), indicating that APLNR antagonists may enhance
the therapeutic efﬁcacy of TMZ.
Pharmacological inhibition of APLNR
by MM54 reduces xenograft
progression
Pharmacodynamics studies revealed that MM54 demon-
strated good solubility in the tested solutions, and was de-
tected in the plasma and the brain in vivo following
intraperitoneal administration in healthy animals
(Supplementary Table 4). Next, to determine the bio-
Figure 4 Continued
(G) Flow cytometry analysis of the percentage of ALDH positive and negative GSC #1 in response to 2, 10 or 20mM of MM54 at Day 5. ALDH
activity corresponds to the percentage of cells that contains ALDH activity (positive) or not (negative), normalized to the vehicle condition.
*P5 0.05; ***P5 0.001 compared to the vehicle condition. (H) Confocal analysis of GSC #1 treated with DMSO or MM54 (2 mM) for
SOX2 (red), NESTIN (green) and nuclei (DAPI, blue). Scale bars = 20mm. (I) Western blot analysis of components of the mTOR and ERK
signalling pathways in GSC#1 with APLN in the presence or absence of MM54 (2 mM). (J) Reverse protein phase array (RPPA) from the TCGA
database were analysed in low and high APLNR expressing glioblastoma samples. *P5 0.05; **P5 0.01 compared to the low APLNR condition.
(K) Western blot analysis of pS9-GSK3b in GSCs #1 and #9 following MM54 treatment in APLN containing MF media. (L) Tumoursphere per field
of view in GSC#1 in response to APLN treatment (1mM) in the presence or absence of the GSK3b inhibitor (tideglusib, 2.5 mM). ***P5 0.001
compared to the MF condition. (M) Linear regression plot of limiting dilution assay (LDA) for GSC #1 in MF and APLN (1 mM) alone or with
tideglusib. (N) GSC #1 received sic (control) or GSK3B targeting siRNA (siGSK3B) and tumoursphere per field of view was quantified in MF
supplemented with purified apelin (APLN, 1 mM). *P5 0.05 compared to the sic MF condition. All panels are representative of n = 3, unless
otherwise specified.
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safety of MM54 in vivo, tumour-bearing mice were admin-
istered 2mg/kg of MM54 bi-weekly for 4 weeks. Due to
the known physiological roles of apelin on the cardiovas-
cular system and glucose metabolism (Maguire et al., 2009;
Scimia et al., 2012; Fournel et al., 2015), cardiac frequency,
blood pressure and glycaemic index were measured. MM54
did not induce alterations to these parameters, reﬂecting no
obvious detrimental action of APLNR antagonism in
tumour-bearing animals (Fig. 6A and B). Complete blood
count analysis revealed no signiﬁcant differences between
mice treated with MM54 and vehicle in healthy animals
(Supplementary Table 5). Similarly, histological and bio-
chemical analysis of heart, kidney and liver revealed no
differences between MM54-treated animals and vehicle
controls (Supplementary Fig. 3), indicating that at the pre-
sent dose following repeated administration, MM54 does
not exert any overt adverse effects in vivo.
We next tested the effect of pharmacological inhibition of
APLNR with MM54 in an ectopic xenograft tumour
model. MM54 treatment dramatically reduced tumour
Figure 5 Pharmacological inhibition of APLNR by MM54 impairs the in vitro expansion of temozolomide-resistant GSCs.
(A) Cell viability following treatment with DMSO, MM54 (2, 20 and 100 mM) or temozolomide (TMZ, 50mM) was measured using UptiBlue in
different cell types for 3 days. Cardiomyocytes (mouse primary cardiomyocytes), keratinocytes (HaCAT), epithelial cells (CaCo2), endothelial
(hCMEC/D3), lymphocyte (Jurkat), neuronal (SH-SY5Y), glial (SVGp12). (B and C) Cell viability following treatment with DMSO or TMZ (100 mM)
was measured using UptiBlue in GSCs #1, #4, #9, and #12 for 3 days. Similar experiments were conducted U87 glioblastoma cell line and GSCs
#1, #4, and #9 grown as spheroids (sph.) in NS medium or as differentiated adherent cells (adh.) in serum-containing medium. (D) GSC#1 viability
was assessed following combined treatment with MM54 (0.2–20 mM) and TMZ (constant ratios TMZ:MM54 2.5:1, 5:1, and 10:1) in NS and human
brain endothelial cell-conditioned medium (EC-CM) conditions. (E and F) Tumoursphere per field of view (fov) and ALDH activity were assessed
in response to MM54 (0.2–100 mM) or TMZ (10–100 mM) treatment at Day 5. (G) Drugs were combined at a constant MM54:TMZ ratio (1:2.5,
1:5, and 1:10) and ALDH activity measured. *P5 0.05 compared to the TMZ 0 condition. (H) Combination index plot for TMZ with MM54.
Combination index (CI) was plotted against fractions affected (Fa) and analysed using COMPUSYN (http://www.combosyn.com/). A result
51 indicated an additive effect of the two compounds, while values closer to 0 suggest the drugs may behave synergistically. (I) Flow cytometry
analysis of ALDH activity in GSC #1 at Day 5 following combined treatment with MM54 (0.5 mM) and the indicated TMZ doses. ALDH activity
corresponds to the percentage of cells that contains ALDH activity (positive) or not (negative). ***P5 0.001 compared to the TMZ 0 condition.
All panels are representative of n = 3, unless otherwise specified.
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growth over 11 weeks when compared to DMSO control
group (Fig. 6C). The decreased tumour volume was asso-
ciated with a reduction in the staining of SOX2 and
NESTIN-positive cells, overall proliferation and viability
that was accompanied by a diminution in tumour vascular-
ization (Fig. 6D and E). Additionally, MM54 treatment led
to a signiﬁcant increase in phospho-GSK3b positive cells
within the tumour (Fig. 6F and G). In line with Zhou
et al’s (2016) studies, this increased GSK3b phosphoryl-
ation was correlated with a decrease in KDM1A levels
(Fig. 6G). To further validate our ﬁndings with MM54,
we tested a second recently developed and structurally dif-
ferent APLNR antagonist, MM193 (Glen and Davenport,
unpublished observation). Increasing doses of MM193 in
GSCs counteracted the effect of apelin on tumourspheres
in vitro (Supplementary Fig. 4A). Moreover, administration
of MM193 (2mg/kg) in GSC#9-inoculated mice resulted in
signiﬁcant impairment of tumour growth compared to ve-
hicle controls (Supplementary Fig. 4B). Likewise, blockade
of APLNR with MM193 did not induce any adverse
Figure 6 Pharmacological inhibition of APLNR by MM54 reduces xenograft progression. (A) Tumour-bearing mice were fasted for
6 h and the effect of either MM54 (2 mg/kg) or DMSO vehicle treatment on glycaemia measured via blood analysis. (B) Cardiac frequency and
blood pressure were measured in random-fed tumour-bearing animals. (C) Nude mice were implanted with GSC#9 (5  105 cells) in each flank
and treated with either DMSO vehicle or the APLNR antagonist (MM54, 2 mg/kg) bi-weekly from Week 4. Tumour volume was measured weekly
until Week 11. n = 10/group. (D and E) Cryosections from GSC tumours were assessed for PECAM (red), Ki67 (green), NESTIN (green), SOX2
(green) and apoptosis (TUNEL). (F) Tumour sections were assessed for pS9-GSK3b staining in DMSO vehicle- and MM54-treated animals. Scale
bars = 40 mm. (G) Western blot analysis of KDM1A and pS9-GSK3b was performed on two independent tumours from each treatment group.
n = 6 mice/group. *P5 0.05; **P5 0.01; ***P5 0.001 compared to the DMSO vehicle control group. All panels are representative of n = 3, unless
specified.
12 | BRAIN 2017: Page 12 of 16 E. Harford-Wright et al.
Downloaded from https://academic.oup.com/brain/article-abstract/doi/10.1093/brain/awx253/4316093/Pharmacological-targeting-of-apelin-impairs
by University of Cambridge user
on 06 October 2017
changes to cardiac frequency, blood pressure or glycaemia
in healthy animals (Supplementary Fig. 4C). Together,
these in vivo data indicate that pharmacological inhibition
of APLNR efﬁciently and safely reduces tumour growth in
xenografted female animals.
Pharmacological blockade of APLNR
by MM54 prolongs survival of
xenografted mice
To gain further insight into the therapeutic potential of
APLNR antagonism in glioblastoma, nude mice were
orthotopically implanted with GSC#9 into the striatum
and treated with MM54 (2mg/kg) three times a week.
Experimental models of brain tumours are commonly asso-
ciated with the development of neurological symptoms as
well as cachexia as the tumour progresses. MM54 treat-
ment was sufﬁcient to impair the development of tumour-
associated neurological symptoms and weight loss (Fig. 7A
and B), which was coupled with a marked reduction in
tumour size (Fig. 7C). Importantly, MM54 administration
signiﬁcantly improved the overall survival of tumour-bear-
ing mice compared to their vehicle-treated counterparts
(Fig. 7D). Additionally, blockade of APLNR was associated
with a reduction in vascularization, proliferation, and
SOX2 and NESTIN-positive cells (Fig. 7E). Collectively,
these in vivo data provide a strong basis for the clinical
potential of apelin/APLNR signalling as a therapeutic target
in glioblastoma.
Discussion
The present study has identiﬁed the vasoactive peptide
apelin as a critical factor involved in glioma growth. It is
now well accepted that GSCs reside in proximity to vascu-
lar beds, into which endothelial cells secrete factors that
regulate their self-renewal and fate. With that view,
apelin is highly expressed in endothelial cells and once
released has been proposed to act as a local mediator
(Kleinz and Davenport, 2005; Kaelin et al., 2007). In keep-
ing with this, a recent study reports the high expression of
apelin in colorectal cancer-isolated endothelial cells, which
further correlates with refractoriness to anti-angiogenic
treatment (Zuurbier et al., 2017). Here, we demonstrate
that apelin is released by human, mouse and tumour-
derived endothelial cells in vitro, although this secretion
Figure 7 Pharmacological blockade of APLNR by MM54 prolongs survival of xenografted mice. (A–E) 105 GSC #9 were implanted
into the striatum of female nude mice and treated three times a week with DMSO or MM54 (2 mg/kg) from Week 3 and the appearance of
neurological symptoms monitored over time (A). The weight of mice at sacrifice was recorded for each treatment group (B). Haematoxylin and
eosin (H&E) staining of tumour-inoculated brains following MM54 (2 mg/kg) or DMSO vehicle treatment (C). Kaplan-Meier survival curve of GSC
#9 bearing mice in response to vehicle or MM54 treatment. n = 6/group. (D) Cryosections of brain tumour tissue stained for PECAM (red),
NESTIN (green), SOX2 (green), Ki67 (red), and DAPI (blue) and quantified. Scale bars = 40 mm. **P5 0.01; ***P5 0.001 compared to the DMSO
control group (E). All panels are representative of n = 3, unless otherwise specified.
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was not overtly affected by the acidiﬁcation of the milieu.
Additionally, we show that apelin increases GSC self-re-
newal in vitro in tumoursphere and limiting dilution
assays, and that this effect appears to be independent of
cell proliferation, consistent with the previously reported
action on microvascular endothelial cells (Kaelin et al.,
2007).
In both subcutaneous ectopic and intracranial orthotopic
xenograft models, inhibition of APLNR was associated
with a signiﬁcant reduction in tumour volume together
with a reduction in vascularization, proliferation and an
increase in apoptosis. Moreover, animals implanted with
APLNR knocked down cells (shAPLNR GSC#9) were asso-
ciated with a reduction in tumour burden compared to
control groups, indicating that APLNR may be intrinsically
important for tumour development. Additionally, APLNR
knockdown and MM54 treatment diminished the number
of NESTIN-positive cells within the xenografts again
strengthening our hypothesis that apelin is particularly es-
sential for the maintenance of GSCs.
Moreover, apelin has been implicated in physiological
and pathological angiogenesis (Kaelin et al., 2007).
Apelin induces proliferation and vessel sprouting in endo-
thelial cells, as well as stabilizing contacts between adjacent
endothelial cells (Kleinz and Davenport, 2005). In keeping
with this, a recent study proposed apelin as a marker for
monitoring tumour vessel normalization and response to
anti-angiogenic therapy (Zhang et al., 2016; Zuurbier
et al., 2017). Accordingly, pharmacological blockade of
apelin (Figs 6, 7 and Supplementary Fig. 3), but not the
reduction of APLNR expression in GSCs (Supplementary
Fig. 2D), may also contribute to the reduction of tumour
volume observed in this study in vivo, by blocking angio-
genesis and depriving tumour cells of the nutrients they
require to survive. Although we cannot discount alternative
sources of apelin peptides are involved in vivo, taken to-
gether the results of this study indicate that endothelial-
derived apelin is an important factor for glioma growth.
The poor response of glioblastoma to chemotherapies has
been in part attributed to the population of resistant initi-
ating cells within the tumour. Therefore, identiﬁcation of
agents that improve GSC sensitivity to TMZ, the current
standard-of-care, is of great interest. It has been reported
that vascular niche maintains GSCs in a quiescent state
thereby protecting them from radiation and chemothera-
pies. Our study demonstrates that the APLNR antagonist
MM54 synergizes with TMZ in vitro. We further demon-
strate that TMZ alone does not alter the activity of the
stem marker ALDH, however when combined with sub-
optimal dose of MM54, we observed profound alterations
in the percentage of ALDH-positive cells. High ALDH1A1
expression has been associated with poor prognosis in glio-
blastoma, and its overexpression in vitro a predictor of
TMZ resistance (Schafer et al., 2012). These alterations
to the stem identity of GSCs suggest that combined treat-
ment with MM54 and TMZ may provide an interesting
opportunity to further target populations of cells currently
resistant to chemotherapeutic drugs.
Although the precise molecular mechanisms that connect
the apelin/APLNR axis to GSC maintenance will require
further investigation, our data suggest that it may act
through the GSK3b signalling pathway. GSK3b was
shown to be upregulated in glioblastoma cells, and assist
in stem cell maintenance by phosphorylating and stabilizing
KDM1A (Zhou et al., 2016). Paralleling the effect of the
GSK3b inhibitor tideglusib (Zhou et al., 2016) (Fig. 4L),
we found that the APLNR antagonist MM54 reduced GSC
self-renewal and potentiated sensitivity to TMZ (Fig. 5).
APLNR inhibition was accompanied by an increased phos-
phorylation of GSK3b at S9, both in vitro and in vivo
further supporting an inhibitory effect of MM54 com-
pound on GSK3b signalling.
Here, we provide evidence that both in vitro and in vivo
inhibition of APLNR results in a signiﬁcant reduction in
tumour growth. Given the concerns about the current
therapeutic regime and the intrinsic resistance to TMZ, tar-
geting apelin signalling presents a new opportunity for use
in the treatment of glioblastoma.
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